Yoshiaki Amino
Overview
Explore the profile of Yoshiaki Amino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miyadera K, Kakuto S, Sugai M, Tsugitomi R, Amino Y, Uchibori K, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518151
A prognostic marker in patients with non-small-cell lung cancer (NSCLC) treated with anti-PD-1/PD-L1 antibodies must be established. This study explored serum cytokeratin fraction 21-1 (CYFRA 21-1), which represents a squamous...
2.
Akita T, Ariyasu R, Kakuto S, Miyadera K, Kiritani A, Tsugitomi R, et al.
Thorac Cancer
. 2024 Feb;
15(10):788-796.
PMID: 38400801
Background: It is difficult to predict gene mutations individually based on clinical background alone. Tumor markers may help to predict each gene mutation. Identifying tumor markers that can predict gene...
3.
Kiritani A, Amino Y, Uchibori K, Akita T, Harutani Y, Ogusu S, et al.
Thorac Cancer
. 2024 Jan;
15(5):402-409.
PMID: 38226415
Background: As an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), osimertinib has emerged as a standard EGFR-mutation positive treatment for non-small cell lung cancer (NSCLC). However, the efficacy of osimertinib...
4.
Amino Y, Low S, Ninomiya H, Kiritani A, Miyadera K, Kakuto S, et al.
Thorac Cancer
. 2023 Sep;
14(33):3317-3322.
PMID: 37751775
Background: KRAS mutation positive lung cancer is known to be clinically characterized by older age, males, and smokers. It is reported to be more common in mucinous adenocarcinoma, but all...
5.
Ariyasu R, Kakuto S, Miyadera K, Akita T, Kiritani A, Tsugitomi R, et al.
JTO Clin Res Rep
. 2023 Jul;
4(6):100524.
PMID: 37426307
Introduction: Only a few reports have determined whether recently advanced anticancer drugs, particularly next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), prolong the survival of patients with NSCLC...
6.
Tozuka T, Yanagitani N, Yoshida H, Manabe R, Ogusu S, Tsugitomi R, et al.
Invest New Drugs
. 2023 Apr;
41(3):411-420.
PMID: 37058183
Soluble interleukin-2 receptor (sIL-2R) suppresses effector T-cells. Few studies have assessed serum sIL-2R in patients receiving immunotherapy. We evaluated the association between serum sIL-2R levels and the efficacy of anti-programmed...
7.
Ogusu S, Ariyasu R, Akita T, Kiritani A, Tsugitomi R, Amino Y, et al.
Invest New Drugs
. 2022 Sep;
40(6):1342-1349.
PMID: 36152107
Data on the re-administration of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) after osimertinib failure in patients with T790M-positive non-small cell lung cancer (NSCLC) is limited. EGFR-TKI re-administration efficacy...
8.
Hashimoto K, Ariyasu R, Ichinose J, Matsuura Y, Nakao M, Amino Y, et al.
J Thorac Cardiovasc Surg
. 2022 Sep;
165(4):1565-1574.e1.
PMID: 36137840
Objectives: We investigated the effect of tyrosine kinase inhibitors (TKIs) and immunotherapy on survival after postoperative recurrence of non-small cell lung cancer (NSCLC). Methods: This single-center retrospective study included patients...
9.
Low S, Ariyasu R, Uchibori K, Hayashi R, Chan H, Chin Y, et al.
Transl Lung Cancer Res
. 2022 Jun;
11(5):711-721.
PMID: 35693289
Background: Genomic profiling of tumors from cancer patients facilitates molecular-guided therapy. The turnaround time is one of important issues to deliver results timely for clinical decisions. The Ion Torrent™ Genexus™...
10.
Toda M, Fujii K, Kato A, Yoshifuji A, Komatsu M, Amino Y, et al.
Kidney Int Rep
. 2021 Oct;
6(10):2733-2734.
PMID: 34622115
No abstract available.